Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
43.5M
-
Number of holders
-
185
-
Total 13F shares, excl. options
-
39.7M
-
Shares change
-
-155K
-
Total reported value, excl. options
-
$1.1B
-
Value change
-
+$4.33M
-
Put/Call ratio
-
4.7
-
Number of buys
-
112
-
Number of sells
-
-92
-
Price
-
$27.67
Significant Holders of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) as of Q2 2025
227 filings reported holding KNSA - Kiniksa Pharmaceuticals International, plc - Common Stock as of Q2 2025.
Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) has 185 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.7M shares
of 43.5M outstanding shares and own 91.29% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (3.91M shares), VANGUARD GROUP INC (3.13M shares), BAKER BROS. ADVISORS LP (2.82M shares), TANG CAPITAL MANAGEMENT LLC (2.33M shares), Fairmount Funds Management LLC (1.77M shares), ACADIAN ASSET MANAGEMENT LLC (1.27M shares), BRAIDWELL LP (1.1M shares), MORGAN STANLEY (1.07M shares), MILLENNIUM MANAGEMENT LLC (1.02M shares), and Pictet Asset Management Holding SA (985K shares).
This table shows the top 185 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.